Studies over the past 50 years revealing the molecular events that promote normal T lymphocyte cycle competence and progression led to a detailed understanding of how cytokines function to regulate normal hematopoietic cell proliferation. During that same period, the molecular and genetic changes introduced by the Philadelphia chromosome in chronic myelogenous leukemia were unraveled, and these have led to an understanding of how mutations that constitutively activate normal cytokine signaling pathways can cause unregulated cell proliferation and malignant transformation. Based on the paradigm established by these data, it is inescapable that going forward, investigators will operate under the hypothesis that transformation of additional cells and tissues will have a similar pathogenesis.
Kendall A. Smith, James D. Griffin
Title and authors | Publication | Year |
---|---|---|
TNFPred: identifying tumor necrosis factors using hybrid features based on word embeddings
TT Nguyen, NQ Le, QT Ho, DV Phan, YY Ou |
BMC Medical Genomics | 2020 |
Evaluating STAT5 Phosphorylation as a Mean to Assess T Cell Proliferation
M Bitar, A Boldt, MT Freitag, B Gruhn, U Köhl, U Sack |
Frontiers in immunology | 2019 |
Mechanistic Insights into CpG DNA and IL-15 Synergy in Promoting B Cell Chronic Lymphocytic Leukemia Clonal Expansion
R Gupta, XJ Yan, J Barrientos, JE Kolitz, SL Allen, K Rai, N Chiorazzi, PK Mongini |
Journal of immunology (Baltimore, Md. : 1950) | 2018 |
Commentary: The Interleukin-2 T Cell System: A New Cell Growth Model
KA Smith |
Frontiers in immunology | 2015 |
Leukemia and Benzene
R Snyder |
International journal of environmental research and public health | 2012 |
MANY CYTOKINES ARE VERY USEFUL THERAPEUTIC TARGETS IN DISEASE
Marc Feldmann |
Journal of Clinical Investigation | 2008 |